BMBF e:Med HaematoOPT "Model-based optimisation and individualisation of treatment strategies in haematology"

Model-based optimization and individualization of treatment strategies in hematology

The BMBF-funded HaematoOPT project aims to demonstrate that models of normal and leukemic hematopoiesis can be used to practically impact clinical decision making. We are building this project on the shoulders of models of the major three hematopoietic cell lineages (i.e. erythropoiesis, granulocytopoiesis, thrompopoiesis and their regulatory growth factors) and on models for hematopoietic stem cells used to describe clonal cell expansion and, based hereon, onset and treatment of clonal diseases, such as chronic myeloid leukemia (CML). Our interdisciplinary consortium brings together mathematical modelers and bioinformaticians with clinical hematologists and biologists. It is our overall objective to demonstrate the clinical potential of the previously developed mathematical models for treatment optimization and individualization in the field of hematology.

© Ingmar Glauche

Herein, we will focus on two major fields of interest:


• Optimizing growth factor treatment of perturbed normal hematopoiesis and
• Optimizing leukemia treatment in acute and chronic myeloid leukemia.

Involved scientists 

• Christoph Baldow

• Hendrik Liebscher

• Ingmar Glauche

• Ingo Röder

• Helene Hoffmann

• Katja Hoffmann

• Katja Tampe

• Sebastian Wagner

• Thomas Zerjatke

Publications

Funding

BMBF (031A424A) Funding within the e:Med Initiative -- Modul II - Demonstratoren für die individualisierte Medizin